Molnupiravir and Favipiravir Analyzed with HPLC - AppNote
October 12, 2021
/
/
/
/
/
Oral Anti-Viral Medications - Easy Reversed Phase Method 

Molnupiravir and Favipiravir, new anti-viral drugs were analyzed by HPLC using a simple Mobile Phase. As shown in the 10 injection overlay in the chromatogram below, the Separation, Peak Shapes and Repeatability are very good (%RSD ≤ 0.2).  


Peaks:
1. Favipiravir
2. Molnupiravir 

Method Conditions:
Column: Cogent RP C18™, 5µm, 100Å
Catalog No.68518-15P
Dimensions: 4.6 x 150mm
Mobile Phase: (75:25) DI Water / Acetonitrile with 0.1% Formic Acid
Injection Volume: 1µL
Flow Rate: 1.0mL / minute
Detection: UV @ 254nm
Sample Preparation: Molnupiravir and Favipiravir are dissolved at a concentration of 0.5mg / mL in (50:50) DI Water / Acetonitrile

Note:  Molnupiravir is an oral antiviral drug that was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. 

Related Articles

  1. Molnupiravir Analyzed with an Inverse Gradient in HPLC - AppNote
  2. Molnupiravir and Favipiravir Analyzed with HPLC - AppNote
  3. Remdesivir and GS-441524 a ProDrug - AppNote

© Copyright 2025. MICROSOLV. All Rights Reserved. Website & Hosting by BlueTone Media